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LETTER TO THE EDITOR
Transforming growth factor ,B isoforms in breast cancer
Sir - The study by MacCallum et al. (1994) on expression of
TGF-P isoforms in breast cancer further highlights the
methodological problems associated with determining the
roles of these multifunctional peptides in both tumour pro-
gression and response to therapeutic interventions. It is
important to distinguish between these two aspects ofTGF-P
function, and this may serve to partially reconcile some of
the disparate opinions on the putative roles of TGF-P iso-
forms in breast cancer.
The issue of the origin of TGF-,B remains particularly
controversial. As with previous studies analysing total RNA
extracted from tumour samples, the data ofMacCallum et al.
(1994) fail to permit any distinction between epithelial and
stromal sources of TGF-P mRNA. The overexpression of
TGF-P in an autocrine capacity by breast epithelial cells is
difficult to reconcile with its inhibitory effects upon
epithelium, and the association of epithelial TGF-P1 expres-
sion with disease progression (Gorsch et al., 1992) may be a
consequence of defective secretion of TGF-,B by carcinoma
cells. Nonetheless, such sources of TGF-P may serve
primarily to promote stromal expansion (including angio-
genesis) and hence tumour growth, especially in more
advanced stages of carcinogenesis. However, in the earlier
and premalignant stages, TGF-P may act predominantly as
an epithelial growth inhibitor via both paracrine influences
from stromal cells and direct autocrine inhibition from
epithelial sources of TGF-,B. In addition, TGF-P mnay inhibit
endothelial proliferation in these earlier lesions (Schultz &
Grant, 1991). Though immunohistochemical studies have re-
vealed minimal intracellular staining of stromal cells
(McCune et al., 1992), this may reflect the nuances of secre-
tion dynamics. Moreover, whatever the role of stromal
sources ofTGF-P in tumour progression, they may constitute
a target for stimulation of local levels of inhibitory growth
factors. In a study from this laboratory (Butta et al., 1992),
we observed minimal staining of stromal cells in pretreatment
samples, but intracellular staining of fibroblasts was clearly
evident following tamoxifen treatment, in addition to marked
up-regulation of extracellular TGF-P (between and around
stromal cells). We have also recently found that primary
cultures of breast tumour fibroblasts are a rich source of
TGF-Pl and that levels of synthesis can be modulated by
tamoxifen (our unpublished data). Such therapeutic induc-
tion ofTGF-P (be it from stromal or epithelial sources) must
be distinguished from growth factor status relating to neo-
plastic progression per se.
It is therefore necessary to investigate tumours not only at
various stages of presentation, but also before and after
treatment interventions. Levels of TGF-13 should be
accurately localised and quantified. The authors concede that
their study is purely qualitative, and that levels of TGF-,B
mRNA may not accurately reflect levels of protein product
owing to post-transcriptional regulation (Knabbe et al., 1987;
Colletta et al., 1990, 1991; Kim et al., 1992). However,
immunohistochemical studies reveal no differences in the pat-
tern of expression of TGF-P isoforms between benign and
malignant breast tissue (Schultz & Grant, 1991), suggesting
that differential quantitative expression is functionally impor-
tant. Even tiny amounts of TGF-P mRNA could yield a
positive signal using the RNAse protection assay method
described in this paper. Furthermore, some functional redun-
dancy may exist within the TGF-P family, with one isoform
being pre-eminent under particular circumstances.
We await with interest the results of immunohistochemical
and in situ hybridisation studies.
J.R. Benson
M. Baum
Section of Surgery,
Institute of Cancer Research,
The Royal Marsden Hospital,
Fulham Road, London SW3 6JJ, UK.
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